The IASLC will host a #TTLC21 highlights meeting for delegates in Europe and Asia on March 3-4-News-CSCO

The IASLC will host a #TTLC21 highlights meeting for delegates in Europe and Asia on March 3-4

PUBLISHED: 2021-03-02 8817 total views, 1 today

Asian Highlights

3 MARCH 2021

13:30 – 14:40 CET Targeted Therapies – EGFR/ ALK/ MET

• Welcome Introduction Tetsuya Mitsudomi, Japan

• EGFR Exon 20 Insertions: Novel TKIs, Amivantamab and Other Treatment Options Zosia Piotrowska, USA

• Persister Biology Christine Lovly, USA

• New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib - New Data and Resistance Mechanisms Ignatius (Sai-Hong) Ou, USA

• MET Rebecca Heist, USA

• Live Panel Discussion

14:40 – 15:40 CET Targeted Therapies – RET/HER2/NRG/NTRK/KRAS

• RET Fusion-Positive Lung Cancers Alex Drilon, USA

• HER2, NTRK, NRG1 "Too Many Topics for a Pun" Stephen Liu, USA

• Sotorasib for KRAS G12C Bob Li, USA

• KRAS G12C Inhibitor Combinations Gregory Riely, USA

• Live Panel Discussion

4 MARCH 2021

13:30 – 14:40 CET The Future of Immunotherapy

• Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40 Rachel Sanborn, USA

• Immunotherapy Combinations CTLA-4, 41BB, ICOS Jarushka Naidoo, Ireland

• Personalized Cancer Vaccines Justin Gainor, USA

• Aiming the Immune System at Mutation-Driven Tumors Charu Aggarwal, USA

• Live Panel Discussion

14:40 – 15:40 CET SCLC/Perioperative/Antibody Drug Conjugates

• New Therapeutic Targets for SCLC Charles Rudin, USA

• Adjuvant Immunotherapy & Chemo-Immunotherapy: Phase 2 Results & Ongoing

Trials Patrick Forde, USA

• Neoadjuvant & Adjuvant TKI Trials Jamie Chaft, USA

• Antibody Drug Conjugates for HER2 & HER3 Pasi Janne, USA

• Live Panel Discussion